Table 2. Surgery vs primary endocrine therapy results.
| Trial | Median follow-up | Surgery n/N | Primary endocrine therapy n/N | HR (95% CI) |
|---|---|---|---|---|
| Surgery primary endocrine therapy | ||||
| Mortality (‘OS’) | ||||
| EORTC 10851 | 10 years | 60/82 | 50/82 | 1.11 (0.75–1.65) |
| Nottingham 1 | 5 years | 28/65 | 28/66 | 1.06 (0.59–1.92) |
| St Georges | 6 years | 28/100 | 33/100 | 0.75 (0.44–1.26) |
| Mortality, recurrence or progression (‘PFS’) | ||||
| EORTC 10851 | 10 years | 63/82 | 69/82 | 0.55 (0.39–0.77) |
| Nottingham 1 | 12 years | 56/65 | 57/66 | Not estimable |
| St Georges | 6 years | 60/100a | 70/100a | Not estimable |
| Local recurrence or local progression as first event | ||||
| EORTC 10851 | 10 years | 7/82 | 47/82 | Not calculatedb |
| Nottingham 1 | 9 years | 16/65a | 45/66a | Not calculatedb |
| St Georges | 6 years | 36/100 | 53/100 | Not calculatedb |
| Distant metastases as first or simultaneous event | ||||
| EORTC 10851 | 10 years | 15/82 | 7/82 | Not calculatedb |
| Nottingham 1 | 12 years | NR | NR | Not calculatedb |
| St Georges | 6 years | 14/100 | 8/100 | Not calculatedb |
OS=overall survival; PFS=progression-free survival.
a
Individual patient data from trial list.
b
Not calculated because of 20–50% competing risks (Nottingham 1 and EORTC 10851) and informative censoring (St Georges). Surgery plus adjuvant endocrine therapy vs primary endocrine therapy.